Vaccines against human respiratory syncytial virus in clinical trials, where are we now?

Rossey, Iebe; Saelens, Xavier

doi:10.1080/14760584.2019.1675520

Cited by 32Respiratory viral infections researchSARS-CoV-2 and COVID-19 ResearchVirology and Viral Diseases

Vaccines against human respiratory syncytial virus in clinical trials, where are we now?

Rossey, Iebe, Saelens, Xavier·2019·Expert Review of Vaccines

DOI 10.1080/14760584.2019.1675520

Open this paper in CoChat — free account

Abstract

Introduction: Human respiratory syncytial virus (RSV) is a major health threat both for the very young and the elderly. With yearly 3.2 million hospital admissions and approximately 118,000 deaths due to RSV in children across the globe, the impact of this infectious disease is very high. Development of a safe RSV vaccine is of utmost importance but has proven to be challenging for several reasons. Researchers are faced with the history of a failed RSV vaccine trial, difficult target populations, a virus that naturally does not induce a long-lasting immune response and ambiguity concerning the optimal correlate of protection. Many different vaccine formats are being tested in preclinical models and about 30 candidate RSV vaccines are being evaluated in clinical trials.Areas covered: In this review we focus on the difficulties concerning the development of an effective RSV vaccine and discuss vaccines that are currently in clinical trials and how they have dealt with these challenges. We review live-attenuated vaccines, vectored vaccines, subunit vaccines and particle-based vaccines.Expert opinion: It is clear that this field is progressing rapidly with several promising RSV vaccine candidates. A safe and effective RSV vaccine might be on the brink of clinical implementation soon.

Integrity signals

Registry

Crossref · 10.1080/14760584.2019.1675520

Cites

129 of 129 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Development of effective vaccines in newborns and young children for respiratory syncytial virus, diarrheal diseases, and tuberculosis has proved challenging.
“the development of effective vaccines in newborns and young children for a variety of diseases [e.g., respiratory syncytial virus,19 diarrheal diseases,20 tuberculosis21] has proved challenging.”
From SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges (2021) · cites this paper as [19]

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis
Nair, H., Nokes, D. J., Gessner, B. D., Dherani, M., Madhi, S. A., Singleton, R. J., O'Brien, K. L., Roca, A., Wright, P. F., Bruce, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60206-1 · Cited by 2,773 · see citing works
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study
Shi, T., McAllister, D., O’Brien, K. L., Simões, E. A. F., Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acácio, S., Aguayo, C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30938-8 · Cited by 2,382 · see citing works
Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults
Falsey, A. R., Hennessey, P., Formica, M. A., Cox, C., & Walsh, E. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043951 · Cited by 2,239 · see citing works
RESPIRATORY SYNCYTIAL VIRUS DISEASE IN INFANTS DESPITE PRIOR ADMINISTRATION OF ANTIGENIC INACTIVATED VACCINE12
KIM, H. W., CANCHOLA, J. G., BRANDT, C. D., PYLES, G., CHANOCK, R. M., JENSEN, K., & PARROTT, R. H. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120955 · Cited by 1,981 · see citing works
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
McLellan, J. S., Chen, M., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. (2013) · Science · doi:10.1126/science.1243283 · Cited by 1,126 · see citing works
AN EPIDEMIOLOGIC STUDY OF ALTERED CLINICAL REACTIVITY TO RESPIRATORY SYNCYTIAL (RS) VIRUS INFECTION IN CHILDREN PREVIOUSLY VACCINATED WITH AN INACTIVATED RS VIRUS VACCINE
Kapikian, A. Z., MITCHELL, R. H., Chanock, R. M., Shvedoff, R. A., & STEWART, C. E. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120954 · Cited by 1,035 · see citing works
Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody
McLellan, J. S., Chen, M., Leung, S., Graepel, K. W., Du, X., Yang, Y., Zhou, T., Baxa, U., Yasuda, E., Beaumont, T., et al. (2013) · Science · doi:10.1126/science.1234914 · Cited by 883 · see citing works
Immunity to and Frequency of Reinfection with Respiratory Syncytial Virus
Hall, C. B., Walsh, E. E., Long, C., & Schnabel, K. C. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/163.4.693 · Cited by 774 · see citing works
Respiratory-Syncytial-Virus Infections, Reinfections and Immunity
Henderson, F. W., Collier, A. M., Clyde, W. A., & Denny, F. W. (1979) · New England Journal of Medicine · doi:10.1056/nejm197903083001004 · Cited by 705 · see citing works
Two Distinct Subtypes of Human Respiratory Syncytial Virus
Mufson, M. A., Örvell, C., Rafnar, B., & Norrby, E. (1985) · Journal of General Virology · doi:10.1099/0022-1317-66-10-2111 · Cited by 664 · see citing works
B-cell responses to vaccination at the extremes of age
Siegrist, C.-A., & Aspinall, R. (2009) · Nature Reviews Immunology · doi:10.1038/nri2508 · Cited by 659 · see citing works
FIELD EVALUATION OF A RESPIRATORY SYNCYTIAL VIRUS VACCINE AND A TRIVALENT PARAINFLUENZA VIRUS VACCINE IN A PEDIATRIC POPULATION1
CHIN, J., Magoffin, R. L., Shearer, L. A., SCHIEBLE, J. H., & Lennette, E. H. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120957 · Cited by 630 · see citing works
RESPIRATORY VIRUS IMMUNIZATION
Fulginiti, V. A., Eller, J. J., Sieber, O. F., Joyner, J. W., Minamitani, M., & Meiklejohn, G. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120956 · Cited by 609 · see citing works
Taxonomy of the order Mononegavirales: update 2016
Afonso, C. L., Amarasinghe, G. K., Bànyai, K., Bào, Y., Basler, C. F., Bavari, S., Bejerman, N., Blasdell, K. R., Briand, F., Briese, T., et al. (2016) · Archives of Virology · doi:10.1007/s00705-016-2880-1 · Cited by 493 · see citing works
Suppression of the Induction of Alpha, Beta, and Gamma Interferons by the NS1 and NS2 Proteins of Human Respiratory Syncytial Virus in Human Epithelial Cells and Macrophages
Spann, K. M., Tran, K.-C., Chi, B., Rabin, R. L., & Collins, P. L. (2004) · Journal of Virology · doi:10.1128/jvi.78.8.4363-4369.2004 · Cited by 447 · see citing works
Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera
Ngwuta, J. O., Chen, M., Modjarrad, K., Joyce, M. G., Kanekiyo, M., Kumar, A., Yassine, H. M., Moin, S. M., Killikelly, A. M., Chuang, G., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4241 · Cited by 433 · see citing works
Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro : Clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant
Karron, R. A., Buonagurio, D. A., Georgiu, A. F., Whitehead, S. S., Adamus, J. E., Clements‐Mann, M. L., Harris, D. O., Randolph, V. B., Udem, S. A., Murphy, B. R., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.13961 · Cited by 420 · see citing works
Identification of nucleolin as a cellular receptor for human respiratory syncytial virus
Tayyari, F., Marchant, D., Moraes, T. J., Duan, W., Mastrangelo, P., & Hegele, R. G. (2011) · Nature Medicine · doi:10.1038/nm.2444 · Cited by 406 · see citing works
A Role for Immune Complexes in Enhanced Respiratory Syncytial Virus Disease
Polack, F. P., Teng, M. N., Collins, P. L., Prince, G. A., Exner, M., Regele, H. M., Lirman, D. D., Rabold, R., Hoffman, S. J., Karp, C. L., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020781 · Cited by 402 · see citing works
Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus.
Graham, B. S., Henderson, G. S., Tang, Y., Lu, X., Neuzil, K. M., & Colley, D. G. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.4.2032 · Cited by 396 · see citing works
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Zhu, Q., McLellan, J. S., Kallewaard, N. L., Ulbrandt, N. D., Palaszynski, S., Zhang, J., Moldt, B., Khan, A. A., Svabek, C., McAuliffe, J. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj1928 · Cited by 364 · see citing works
Occurrence of Groups A and B of Respiratory Syncytial Virus over 15 Years: Associated Epidemiologic and Clinical Characteristics in Hospitalized and Ambulatory Children
Hall, C. B., Walsh, E. E., Schnabel, K. C., Long, C., McConnochie, K. M., Hildreth, S. W., & Anderson, L. J. (1990) · The Journal of Infectious Diseases · doi:10.1093/infdis/162.6.1283 · Cited by 345 · see citing works
A proof of concept for structure-based vaccine design targeting RSV in humans
Crank, M. C., Ruckwardt, T. J., Chen, M., Morabito, K. M., Phung, E., Costner, P. J., Holman, L. A., Hickman, S. P., Berkowitz, N. M., Gordon, I. J., et al. (2019) · Science · doi:10.1126/science.aav9033 · Cited by 333 · see citing works
Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine
Murphy, B. R., Prince, G. A., Walsh, E. E., Kim, H. W., Parrott, R. H., Hemming, V. G., Rodriguez, W. J., & Chanock, R. M. (1986) · Journal of Clinical Microbiology · doi:10.1128/jcm.24.2.197-202.1986 · Cited by 307 · see citing works
RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection
Jóźwik, A., Habibi, M. S., Paras, A., Zhu, J., Guvenel, A., Dhariwal, J., Almond, M., Wong, E., Sykes, A., Maybeno, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms10224 · Cited by 303 · see citing works
Impaired Antibody-Mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus
Habibi, M. S., Jóźwik, A., Makris, S., Dunning, J. W., Paras, A., DeVincenzo, J. P., de Haan, C. A. M., Wrammert, J., Openshaw, P., & Chiu, C. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201412-2256oc · Cited by 289 · see citing works
Identification of a Recombinant Live Attenuated Respiratory Syncytial Virus Vaccine Candidate That Is Highly Attenuated in Infants
Karron, R. A., Wright, P. F., Belshe, R. B., Thumar, B., Casey, R., Newman, F. K., Polack, F. P., Randolph, V. B., Deatly, A. M., Hackell, J. G., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/427813 · Cited by 286 · see citing works
The M2–2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription
Bermingham, A., & Collins, P. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11259 · Cited by 278 · see citing works
Respiratory Syncytial Virus Genetic and Antigenic Diversity
Sullender, W. M. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.1.1-15.2000 · Cited by 275 · see citing works
Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention
Magro, M., Mas, V., Chappell, K., Vázquez, M., Cano, O., Luque, D., Terrón, M. C., Melero, J. A., & Palomo, C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115941109 · Cited by 271 · see citing works
The Fusion Glycoprotein of Human Respiratory Syncytial Virus Facilitates Virus Attachment and Infectivity via an Interaction with Cellular Heparan Sulfate
Feldman, S. A., Audet, S. A., & Beeler, J. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.14.6442-6447.2000 · Cited by 270 · see citing works
Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors
Gilman, M. S. A., Castellanos, C. A., Chen, M., Ngwuta, J. O., Goodwin, E. C., Moin, S. M., Más, V., Melero, J. A., Wright, P. F., Graham, B. S., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaj1879 · Cited by 239 · see citing works
Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine
Prince, G. A., Curtis, S. J., Yim, K. C., & Porter, D. D. (2001) · Journal of General Virology · doi:10.1099/0022-1317-82-12-2881 · Cited by 237 · see citing works
Recombinant Respiratory Syncytial Virus Bearing a Deletion of either the NS2 or SH Gene Is Attenuated in Chimpanzees
Whitehead, S. S., Bukreyev, A. A., Teng, M. N., Firestone, C.-Y., Claire, M. S., Elkins, W. R., Collins, P. L., & Murphy, B. R. (1999) · Journal of Virology · doi:10.1128/jvi.73.4.3438-3442.1999 · Cited by 237 · see citing works
Maternal antibody and respiratory syncytial virus infection in infancy
OGILVIE, M. M., Vathenen, A. S., Radford, M., Codd, J. D., & Key, S. (1981) · Journal of Medical Virology · doi:10.1002/jmv.1890070403 · Cited by 227 · see citing works
Respiratory Syncytial Virus Genetic and Antigenic Diversity
Sullender, W. M. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.1.1 · Cited by 227 · see citing works
Contribution of the Respiratory Syncytial Virus G Glycoprotein and Its Secreted and Membrane-Bound Forms to Virus Replication in Vitro and in Vivo
Teng, M. N., Whitehead, S. S., & Collins, P. L. (2001) · Virology · doi:10.1006/viro.2001.1138 · Cited by 225 · see citing works
Erratum: RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection
Jóźwik, A., Habibi, M. S., Paras, A., Zhu, J., Guvenel, A., Dhariwal, J., Almond, M., Wong, E., Sykes, A., Maybeno, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms11011 · Cited by 223 · see citing works
Respiratory Syncytial Virus Infection in Elderly Adults
Falsey, A. R., & Walsh, E. E. (2005) · Drugs & Aging · doi:10.2165/00002512-200522070-00004 · Cited by 222 · see citing works
Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness.
Mills, J., Kirk, J. E. V., Wright, P. F., & Chanock, R. M. (1971) · PubMed · Cited by 211 · see citing works
Evaluation of Two Live, Cold‐Passaged, Temperature‐Sensitive Respiratory Syncytial Virus Vaccines in Chimpanzees and in Human Adults, Infants, and Children
Karron, R. A., Wright, P. F., Crowe, J. E., Clements‐Mann, M. L., Thompson, J., Makhene, M., Casey, R., & Murphy, B. R. (1997) · The Journal of Infectious Diseases · doi:10.1086/514138 · Cited by 208 · see citing works
Recombinant Respiratory Syncytial Virus That Does Not Express the NS1 or M2-2 Protein Is Highly Attenuated and Immunogenic in Chimpanzees
Teng, M. N., Whitehead, S. S., Bermingham, A., Claire, M. S., Elkins, W. R., Murphy, B. R., & Collins, P. L. (2000) · Journal of Virology · doi:10.1128/jvi.74.19.9317-9321.2000 · Cited by 202 · see citing works
Mortality Attributable to 9 Common Infections: Significant Effect of Influenza A, Respiratory Syncytial Virus, Influenza B, Norovirus, and Parainfluenza in Elderly Persons
van Asten, L., van den Wijngaard, C., van Pelt, W., van de Kassteele, J., Meijer, A., van der Hoek, W., Kretzschmar, M., & Koopmans, M. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis415 · Cited by 196 · see citing works
Respiratory Syncytial Virus Transplacental Antibody Transfer and Kinetics in Mother-Infant Pairs in Bangladesh
Chu, H. Y., Steinhoff, M. C., Magaret, A., Zaman, K., Roy, E., LANGDON, G. C., Formica, M. A., Walsh, E. E., & Englund, J. A. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu316 · Cited by 187 · see citing works
The Secreted Form of Respiratory Syncytial Virus G Glycoprotein Helps the Virus Evade Antibody-Mediated Restriction of Replication by Acting as an Antigen Decoy and through Effects on Fc Receptor-Bearing Leukocytes
Bukreyev, A. A., Yang, L., Fricke, J., Cheng, L., Ward, J. M., Murphy, B. R., & Collins, P. L. (2008) · Journal of Virology · doi:10.1128/jvi.01604-08 · Cited by 181 · see citing works
Humoral and Mucosal Immunity in Protection from Natural Respiratory Syncytial Virus Infection in Adults
Walsh, E. E., & Falsey, A. R. (2004) · The Journal of Infectious Diseases · doi:10.1086/421524 · Cited by 181 · see citing works
Immunopathogenesis of vaccine-enhanced RSV disease
Openshaw, P., Culley, F. J., & Olszewska, W. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00301-2 · Cited by 172 · see citing works
RSV Vaccine-Enhanced Disease Is Orchestrated by the Combined Actions of Distinct CD4 T Cell Subsets
Knudson, C. J., Hartwig, S. M., Meyerholz, D. K., & Varga, S. M. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004757 · Cited by 172 · see citing works
Experimental Respiratory Syncytial Virus Infection of Adults
Mills, J., Kirk, J. E. V., Wright, P. F., Chanock, R. M., & Fishburne, I. E. (1971) · The Journal of Immunology · doi:10.4049/jimmunol.107.1.123 · Cited by 164 · see citing works
The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein G are synthesized from alternative initiation codons
Roberts, S. R., Lichtenstein, D. L., Ball, L. A., & Wertz, G. W. (1994) · Journal of Virology · doi:10.1128/jvi.68.7.4538-4546.1994 · Cited by 160 · see citing works
The Small Hydrophobic Protein of the Human Respiratory Syncytial Virus Forms Pentameric Ion Channels
Gan, S. W., Tan, E., Lin, X., Yu, D., Wang, J., Tan, G., Vararattanavech, A., Yeo, C. Y., Soon, C. H., Soong, T. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.332791 · Cited by 160 · see citing works
The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines
Wright, P. F., Karron, R. A., Belshe, R. B., Shi, J. R., Randolph, V. B., Collins, P. L., O’Shea, A., Gruber, W. C., & Murphy, B. R. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.08.014 · Cited by 157 · see citing works
A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age
Glenn, G. M., Fries, L. F., Thomas, D. N., Smith, G., Kpamegan, E. P., Lu, H., Flyer, D. C., Jani, D., Hickman, S. P., & Piedra, P. A. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv406 · Cited by 152 · see citing works
Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus
Killikelly, A. M., Kanekiyo, M., & Graham, B. S. (2016) · Scientific Reports · doi:10.1038/srep34108 · Cited by 151 · see citing works
Respiratory Syncytial Virus Fusion Glycoprotein Expressed in Insect Cells Form Protein Nanoparticles That Induce Protective Immunity in Cotton Rats
Smith, G., Raghunandan, R., Wu, Y., Liu, Y., Massare, M. J., Nathan, M., Zhou, B., Lu, H., Boddapati, S., Li, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050852 · Cited by 149 · see citing works
Live-Attenuated Respiratory Syncytial Virus Vaccines
Karron, R. A., Buchholz, U. J., & Collins, P. L. (2013) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-38919-1_13 · Cited by 147 · see citing works
Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats
Prince, G. A., Hemming, V. G., Horswood, R. L., Baron, P. A., & Chanock, R. M. (1987) · Journal of Virology · doi:10.1128/jvi.61.6.1851-1854.1987 · Cited by 146 · see citing works
Role of Type I Interferon (IFN) in the Respiratory Syncytial Virus (RSV) Immune Response and Disease Severity
Hijano, D. R., Vu, L. D., Kauvar, L. M., Tripp, R. A., Polack, F. P., & Cormier, S. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00566 · Cited by 133 · see citing works
Respiratory Syncytial Virus Nonstructural Proteins Decrease Levels of Multiple Members of the Cellular Interferon Pathways
Swedan, S. F., Musiyenko, A., & Barik, S. (2009) · Journal of Virology · doi:10.1128/jvi.00715-09 · Cited by 132 · see citing works
An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults
Falloon, J., Yu, J. H., Esser, M. T., Villafana, T. L., Li, Y., Dubovsky, F., Takas, T., Levin, M. J., & Falsey, A. R. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix503 · Cited by 131 · see citing works
Chimpanzee adenovirus– and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults
Green, C., Scarselli, E., Sande, C., Thompson, A., de Lara, C. M., Taylor, K., Haworth, K., Sorbo, M. D., Angus, B., Siani, L., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5745 · Cited by 129 · see citing works
Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children
Wright, P. F., Belshe, R. B., Kim, H. W., VORIS, L. P. V., & Chanock, R. M. (1982) · Infection and Immunity · doi:10.1128/iai.37.1.397-400.1982 · Cited by 129 · see citing works
Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG
Bueno, S. M., González, P. A., Cautivo, K. M., Mora, J. E., Leiva, E., Tobar, H. E., Fennelly, G. J., Eugenín, E. A., Jacobs, W. R., Riedel, C. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806244105 · Cited by 127 · see citing works
Comparison of Antibody Concentrations and Protective Activity of Respiratory Syncytial Virus Immune Globulin and Conventional Immune Globulin
Siber, G. R., Leombruno, D., Leszczynski, J., McIver, J., Bodkin, D. K., Gonin, R., Thompson, C. M., Walsh, E. E., Piedra, P. A., Hemming, V. G., et al. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/169.6.1368 · Cited by 124 · see citing works
SAFETY AND ANTIGENICITY OF TEMPERATURE SENSITIVE (TS) MUTANT RESPIRATORY SYNCYTIAL VIRUS (RSV) IN INFANTS AND CHILDREN
Kim, H. W., Arrobio, J. O., Brandt, C. D., Wright, P. F., Hodes, D. S., Chanock, R. M., & Parrott, R. H. (1973) · PEDIATRICS · doi:10.1542/peds.52.1.56 · Cited by 119 · see citing works
Respiratory Syncytial Virus with the Fusion Protein as Its only Viral Glycoprotein Is Less Dependent on Cellular Glycosaminoglycans for Attachment than Complete Virus
Techaarpornkul, S., Collins, P. L., & Peeples, M. E. (2002) · Virology · doi:10.1006/viro.2001.1340 · Cited by 118 · see citing works
CLINICAL AND IMMUNOLOGICAL RESPONSE OF INFANTS AND CHILDREN TO ADMINISTRATION OF LOW- TEMPERATURE ADAPTED RESPIRATORY SYNCYTIAL VIRUS
Kim, H. W., Arrobio, J. O., Pyles, G., Brandt, C. D., Camargo, E., Chanock, R. M., & Parrott, R. H. (1971) · PEDIATRICS · doi:10.1542/peds.48.5.745 · Cited by 117 · see citing works
A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children
Karron, R. A., Luongo, C., Thumar, B., Loehr, K., Englund, J. A., Collins, P. L., & Buchholz, U. J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac8463 · Cited by 114 · see citing works
Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants
Wright, P. F., Shinozaki, T., Fleet, W. F., SELL, S. H. W., Thompson, J., & Karzon, D. T. (1976) · The Journal of Pediatrics · doi:10.1016/s0022-3476(76)81044-x · Cited by 103 · see citing works
Phase 1 Study of the Safety and Immunogenicity of a Live, Attenuated Respiratory Syncytial Virus and Parainfluenza Virus Type 3 Vaccine in Seronegative Children
Bernstein, D. I., Malkin, E. M., Abughali, N., Falloon, J., Yi, T., & Dubovsky, F. (2011) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31823386f1 · Cited by 102 · see citing works
Low-Temperature-Grown RS Virus in Adult Volunteers
Friedewald, W. T. (1968) · JAMA · doi:10.1001/jama.1968.03140210044011 · Cited by 98 · see citing works
Effects of Human Metapneumovirus and Respiratory Syncytial Virus Antigen Insertion in Two 3′ Proximal Genome Positions of Bovine/Human Parainfluenza Virus Type 3 on Virus Replication and Immunogenicity
Tang, R. S., Schickli, J. H., MacPhail, M., Fernandes, F., Bicha, L., Spaete, J. P., Fouchier, R. A. M., Osterhaus, A. D. M. E., Spaete, R. R., & Haller, A. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.10819-10828.2003 · Cited by 98 · see citing works
The small hydrophobic (SH) protein accumulates within lipid-raft structures of the Golgi complex during respiratory syncytial virus infection
Rixon, H. W. M., Brown, G., Aitken, J. D., McDonald, T. P., Graham, S. Y., & Sugrue, R. J. (2004) · Journal of General Virology · doi:10.1099/vir.0.19769-0 · Cited by 98 · see citing works
A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age
August, A., Glenn, G. M., Kpamegan, E. P., Hickman, S. P., Jani, D., Lu, H., Thomas, D. N., Wen, J., Piedra, P. A., & Fries, L. F. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.05.045 · Cited by 98 · see citing works
Breastfeeding reduces the severity of respiratory syncytial virus infection among young infants: A multi‐center prospective study
Nishimura, T., Suzue, J., & Kaji, H. (2009) · Pediatrics International · doi:10.1111/j.1442-200x.2009.02877.x · Cited by 93 · see citing works
Bacterium-Like Particles for Efficient Immune Stimulation of Existing Vaccines and New Subunit Vaccines in Mucosal Applications
Budimir, N., Haijema, B. J., & Leenhouts, K. J. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00282 · Cited by 87 · see citing works
Respiratory Syncytial Virus Modified by Deletions of the NS2 Gene and Amino Acid S1313 of the L Polymerase Protein Is a Temperature-Sensitive, Live-Attenuated Vaccine Candidate That Is Phenotypically Stable at Physiological Temperature
Luongo, C., Winter, C. C., Collins, P. L., & Buchholz, U. J. (2012) · Journal of Virology · doi:10.1128/jvi.02769-12 · Cited by 86 · see citing works
Vaccination strategies against respiratory syncytial virus
Yamin, D., Jones, F. K., DeVincenzo, J. P., Gertler, S., Kobiler, O., Townsend, J. P., & Galvani, A. P. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522597113 · Cited by 85 · see citing works
Temperature-sensitive Mutants of Respiratory Syncytial Virus
Gharpure, M. A., Wright, P. F., & Chanock, R. M. (1969) · Journal of Virology · doi:10.1128/jvi.3.4.414-421.1969 · Cited by 84 · see citing works
Efficient Lung Recruitment of Respiratory Syncytial Virus-Specific Th1 Cells Induced by Recombinant Bacillus Calmette-Guérin Promotes Virus Clearance and Protects from Infection
Cautivo, K. M., Bueno, S. M., Cortes, C. M., Wozniak, A., Riedel, C. A., & Kalergis, A. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903452 · Cited by 80 · see citing works
Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines
Watt, P. J., Robinson, B. S., Pringle, C. R., & Tyrrel, D. A. J. (1990) · Vaccine · doi:10.1016/0264-410x(90)90051-m · Cited by 78 · see citing works
Conservation of G-Protein Epitopes in Respiratory Syncytial Virus (Group A) Despite Broad Genetic Diversity: Is Antibody Selection Involved in Virus Evolution?
Trento, A., Ábrego, L., Fernández, R. R., González-Sánchez, M. I., Martínez, F. G., Delfraro, A., Pascale, J. M., Arbiza, J., & Melero, J. A. (2015) · Journal of Virology · doi:10.1128/jvi.00467-15 · Cited by 77 · see citing works
Granulocyte-Macrophage Colony-Stimulating Factor Expressed by Recombinant Respiratory Syncytial Virus Attenuates Viral Replication and Increases the Level of Pulmonary Antigen-Presenting Cells
Bukreyev, A. A., Belyakov, I. M., Berzofsky, J. A., Murphy, B. R., & Collins, P. L. (2001) · Journal of Virology · doi:10.1128/jvi.75.24.12128-12140.2001 · Cited by 76 · see citing works
Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in Children
McFarland, E. J., Karron, R. A., Muresan, P., Cunningham, C. K., VALENTINE, M. E., Perlowski, C., Thumar, B., Gnanashanmugam, D., Siberry, G. K., Schappell, E., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy040 · Cited by 76 · see citing works
Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults
Fries, L. F., Shinde, V., Stoddard, J. J., Thomas, D. N., Kpamegan, E. P., Lu, H., Smith, G., Hickman, S. P., Piedra, P. A., & Glenn, G. M. (2017) · Immunity & Ageing · doi:10.1186/s12979-017-0090-7 · Cited by 75 · see citing works
Respiratory Syncytial Virus Proteins Modulate Suppressors of Cytokine Signaling 1 and 3 and the Type I Interferon Response to Infection by a Toll-Like Receptor Pathway
Oshansky, C. M., Krunkosky, T. M., Barber, J. P., Jones, L. P., & Tripp, R. A. (2009) · Viral Immunology · doi:10.1089/vim.2008.0098 · Cited by 74 · see citing works
Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development
Melero, J. A., Más, V., & McLellan, J. S. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.09.045 · Cited by 73 · see citing works
An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice
Boyoglu-Barnum, S., Todd, S. O., Chirkova, T., Barnum, T. R., Gaston, K. A., Haynes, L. M., Tripp, R. A., Moore, M. L., & Anderson, L. J. (2015) · Virology · doi:10.1016/j.virol.2015.02.035 · Cited by 72 · see citing works
Sendai virus-based RSV vaccine protects African green monkeys from RSV infection
Jones, B. G., Sealy, R. E., Rudraraju, R., Traina‐Dorge, V., Finneyfrock, B. W., Cook, A., Takimoto, T., Portner, A., & Hurwitz, J. L. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.11.046 · Cited by 72 · see citing works
A Novel Inactivated Intranasal Respiratory Syncytial Virus Vaccine Promotes Viral Clearance without Th2 Associated Vaccine-Enhanced Disease
Lindell, D. M., Morris, S. B., White, M. P., Kallal, L. E., Lundy, P. K., Hamouda, T., Baker, J. R., & Lukacs, N. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021823 · Cited by 72 · see citing works
PHASE-I STUDY MEDI-534, OF A LIVE, ATTENUATED INTRANASAL VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUS AND PARAINFLUENZA-3 VIRUS IN SEROPOSITIVE CHILDREN
Gomez, M. M., Mufson, M. A., Dubovsky, F., Knightly, C., Zeng, W., & Losonsky, G. A. (2009) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e318199c3b1 · Cited by 70 · see citing works
Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV
Waris, M. E., Tsou, C., Erdman, D. D., Day, D. B., & Anderson, L. J. (1997) · Journal of Virology · doi:10.1128/jvi.71.9.6935-6939.1997 · Cited by 70 · see citing works
Breast Milk Prefusion F Immunoglobulin G as a Correlate of Protection Against Respiratory Syncytial Virus Acute Respiratory Illness
Mazur, N. I., Horsley, N., Englund, J. A., Nederend, M., Magaret, A., Kumar, A., Jacobino, S. R., de Haan, C. A. M., Khatry, S. K., LeClerq, S. C., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy477 · Cited by 70 · see citing works
The Secreted G Protein of Human Respiratory Syncytial Virus Antagonizes Antibody-Mediated Restriction of Replication Involving Macrophages and Complement
Bukreyev, A. A., Yang, L., & Collins, P. L. (2012) · Journal of Virology · doi:10.1128/jvi.01162-12 · Cited by 68 · see citing works
Transmissible Viral Vaccines
Bull, J. J., Smithson, M. W., & Nuismer, S. L. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.09.007 · Cited by 68 · see citing works
HLA‐Restricted CD8+Cytotoxic T Lymphocyte, Interferon‐γ, and Interleukin‐4 Responses to Respiratory Syncytial Virus Infection in Infants and Children
Mbawuike, I. N., Wells, J. M., Byrd, R. L., Cron, S. G., Glezen, W. P., & Piedra, P. A. (2001) · The Journal of Infectious Diseases · doi:10.1086/318815 · Cited by 67 · see citing works
A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant
Langley, J. M., Aggarwal, N., Toma, A., Halperin, S. A., McNeil, S., Fissette, L. A., Dewé, W., Leyssen, M., Toussaint, J.-F., & Dieussaert, I. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw453 · Cited by 65 · see citing works
A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice
Céspedes, P. F., Rey-Jurado, E., Espinoza, J. A., Rivera, C. A., Canedo-Marroquín, G., Bueno, S. M., & Kalergis, A. M. (2017) · Vaccine · doi:10.1016/j.vaccine.2016.12.048 · Cited by 65 · see citing works
Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children
Buchholz, U. J., Cunningham, C. K., Muresan, P., Gnanashanmugam, D., Sato, P., Siberry, G. K., Rexroad, V., VALENTINE, M. E., Perlowski, C., Schappell, E., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy066 · Cited by 65 · see citing works
Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults
Green, C., Scarselli, E., Voysey, M., Capone, S., Vitelli, A., Nicosia, A., Cortese, R., Thompson, A., Sande, C., de Lara, C., et al. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008748 · Cited by 60 · see citing works
Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats
Widjojoatmodjo, M. N., Bogaert, L., Meek, B., Zahn, R. C., Vellinga, J., Custers, J. H. H. V., Serroyen, J., Radošević, K., & Schuitemaker, H. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.08.056 · Cited by 59 · see citing works
A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study
Langley, J. M., MacDonald, L. D., Weir, G. M., MacKinnon‐Cameron, D., Ye, L., McNeil, S., Schepens, B., Saelens, X., Stanford, M. M., & Halperin, S. A. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy177 · Cited by 59 · see citing works
Self-citation
Increased Genetic and Phenotypic Stability of a Promising Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate by Reverse Genetics
Luongo, C., Winter, C. C., Collins, P. L., & Buchholz, U. J. (2012) · Journal of Virology · doi:10.1128/jvi.01227-12 · Cited by 58 · see citing works
A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats
Widjojoatmodjo, M. N., Boes, J., van Bers, M., van Remmerden, Y., Roholl, P. J. M., & Luytjes, W. (2010) · Virology Journal · doi:10.1186/1743-422x-7-114 · Cited by 57 · see citing works
Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein
Schepens, B., Sedeyn, K., Ginste, L. V., Baets, S. D., Schotsaert, M., Roose, K., Houspie, L., Ranst, M. A. V., Gilbert, B. E., van Rooijen, N., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404005 · Cited by 57 · see citing works
Self-citation
Partial Attenuation of Respiratory Syncytial Virus with a Deletion of a Small Hydrophobic Gene Is Associated with Elevated Interleukin-1β Responses
Russell, R. F., McDonald, J. U., Ivanova, M., Zhong, Z., Bukreyev, A. A., & Tregoning, J. S. (2015) · Journal of Virology · doi:10.1128/jvi.01070-15 · Cited by 56 · see citing works
Nanoparticle Vaccines Encompassing the Respiratory Syncytial Virus (RSV) G Protein CX3C Chemokine Motif Induce Robust Immunity Protecting from Challenge and Disease
Jorquera, P. A., Choi, Y., Oakley, K. E., Powell, T., Boyd, J. G., Palath, N., Haynes, L. M., Anderson, L. J., & Tripp, R. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074905 · Cited by 54 · see citing works
Local and Systemic Immunity against Respiratory Syncytial Virus Induced by a Novel Intranasal Vaccine. A Randomized, Double-Blind, Placebo-controlled Clinical Trial
Ascough, S., Vlachantoni, I. T., Kalyan, M., Haijema, B. J., Wallin-Weber, S., Dijkstra‐Tiekstra, M. J., Ahmed, M. S., van Roosmalen, M. L., Grimaldi, R., Zhang, Q., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201810-1921oc · Cited by 53 · see citing works
Efficacy of a respiratory syncytial virus vaccine candidate in a maternal immunization model
Blanco, J. C. G., Pletneva, L. M., McGinnes, L. W., Otoa, R. O., Patel, M. C., Fernando, L. R., Boukhvalova, M. S., & Morrison, T. G. (2018) · Nature Communications · doi:10.1038/s41467-018-04216-6 · Cited by 50 · see citing works
A Cold-Passaged, Attenuated Strain of Human Respiratory Syncytial Virus Contains Mutations in the F and L Genes
Connors, M., Crowe, J. E., Firestone, C.-Y., Murphy, B. R., & Collins, P. L. (1995) · Virology · doi:10.1006/viro.1995.1178 · Cited by 46 · see citing works
Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials
Beran, J., Lickliter, J. D., Schwarz, T. F., Johnson, C., Chu, L., Domachowske, J. B., Damme, P. V., Withanage, K., Fissette, L. A., David, M., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy065 · Cited by 46 · see citing works
Cost and burden of RSV related hospitalisation from 2012 to 2017 in the first year of life in Lyon, France
Kramer, R., Duclos, A., Lina, B., & Casalegno, J. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.09.029 · Cited by 45 · see citing works
Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults
Green, C., Sande, C., Scarselli, E., Capone, S., Vitelli, A., Nicosia, A., Silva-Reyes, L., Thompson, A., de Lara, C. M., Taylor, K., et al. (2019) · Journal of Infection · doi:10.1016/j.jinf.2019.02.003 · Cited by 45 · see citing works
Safety and Immunogenicity of an Intranasal Sendai Virus-Based Human Parainfluenza Virus Type 1 Vaccine in 3- to 6-Year-Old Children
Adderson, E. E., Branum, K. C., Sealy, R. E., Jones, B. G., Surman, S. L., Penkert, R. R., Freiden, P. J., Slobod, K. S., Gaur, A. H., Hayden, R. T., et al. (2014) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00618-14 · Cited by 41 · see citing works
Long-term Assessment of Healthcare Utilization 5 Years After Respiratory Syncytial Virus Infection in US Infants
Simões, E. A. F., Chirikov, V., Botteman, M. F., Kwon, Y., & Kuznik, A. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz278 · Cited by 40 · see citing works
Effects of Anti-G and Anti-F Antibodies on Airway Function after Respiratory Syncytial Virus Infection
Han, J., Takeda, K., Wang, M., Zeng, W., Jia, Y., Shiraishi, Y., Okamoto, M., Dakhama, A., & Gelfand, E. W. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0360oc · Cited by 35 · see citing works
Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States
Parikh, R. C., McLaurin, K. K., Margulis, A. V., Mauskopf, J., Ambrose, C. S., Pavilack, M., & Candrilli, S. D. (2017) · Infectious Diseases and Therapy · doi:10.1007/s40121-017-0167-9 · Cited by 33 · see citing works
Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study
Leroux-Roels, G. G., Boever, F. D., Maes, C., Nguyên, T. L.-A., Baker, S. A., & Lopez, A. G. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.011 · Cited by 32 · see citing works
Codon stabilization analysis of the “248” temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates
Luongo, C., Yang, L., Winter, C. C., Spann, K. M., Murphy, B. R., Collins, P. L., & Buchholz, U. J. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.07.022 · Cited by 31 · see citing works
Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation
Blais, N., Gagné, M., Hamuro, Y., Rheault, P., Boyer, M., Steff, A., Baudoux, G., Dewar, V., Demers, J., Ruelle, J.-L., et al. (2017) · Journal of Virology · doi:10.1128/jvi.02437-16 · Cited by 29 · see citing works
Orally administered adenoviral-based vaccine induces respiratory mucosal memory and protection against RSV infection in cotton rats
Joyce, C., Scallan, C. D., Mateo, R., Belshe, R. B., Tucker, S. N., & Moore, A. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.05.112 · Cited by 26 · see citing works
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge
Gilbert, B. E., Patel, N., Lu, H., Liu, Y., Guebre‐Xabier, M., Piedra, P. A., Glenn, G. M., Ellingsworth, L. R., & Smith, G. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.10.073 · Cited by 26 · see citing works
Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods
Smith, T. R. F., Schultheis, K., & Broderick, K. E. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1363134 · Cited by 18 · see citing works
CD4+T Cells Drive Lung Disease Enhancement Induced by Immunization with Suboptimal Doses of Respiratory Syncytial Virus Fusion Protein in the Mouse Model
Schneider-Ohrum, K., Bennett, A. S., Rajani, G. M., Hostetler, L., Maynard, S. K., Lazzaro, M., Cheng, L., O’Day, T. L., & Cayatte, C. (2019) · Journal of Virology · doi:10.1128/jvi.00695-19 · Cited by 16 · see citing works
RSV Vaccine Based on Rhabdoviral Vector Protects after Single Immunization
Wilmschen, S., Schneider, S., Peters, F., Bayer, L., Issmail, L., Bánki, Z., Grünwald, T., von Laer, D., & Kimpel, J. (2019) · Vaccines · doi:10.3390/vaccines7030059 · Cited by 16 · see citing works
Genetic stability determinants of temperature sensitive, live attenuated respiratory syncytial virus vaccine candidates
Lin, Y.-H., Deatly, A. M., Chen, W., Miller, L. Z., Lerch, R. A., Sidhu, M. S., Udem, S. A., & Randolph, V. B. (2005) · Virus Research · doi:10.1016/j.virusres.2005.06.013 · Cited by 15 · see citing works
Comparative study of poliovirus excretion after vaccination of infants with two oral polio vaccines prepared on vero cells or on primary monkey kidney cells
Mallet, L., Pelloquin, F., Brigaud, M., Caudrelier, P., Bandet, R., Xueref, C., Fuchs, F., Gibelin, N., Goldman, C., Moulin, J.-C., et al. (1997) · Journal of Medical Virology · doi:10.1002/(sici)1096-9071(199705)52:1 · Cited by 15 · see citing works
Respiratory Syncytial Virus Fusion Protein-encoding DNA Vaccine Is Less Effective in Conferring Protection against Inflammatory Disease than a Virus-like Particle Platform
Kwon, Y., Hwang, H. S., Lee, Y., Kim, K., Lee, Y., Kim, M., Lee, Y., Quan, F., Moore, M. L., & Kang, S. (2019) · Immune Network · doi:10.4110/in.2019.19.e18 · Cited by 8 · see citing works
Safety and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine Respiratory Syncytial Virus (RSV) Cps2 in RSV-Seronegative Infants and Children
Cunningham, C. K., Buchholz, U. J., Muresan, P., McFarland, E. J., Luongo, C., Collins, P. M., Thumar, B., Schappell, E., Gnanashanmugam, D., Siberry, G. K., et al. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv133.1469 · Cited by 1 · see citing works

Flagged first, then by citations

Sorted by citations

The Future of Respiratory Syncytial Virus Disease Prevention and Treatment
Domachowske, J. B., Anderson, E. J., & Goldstein, M. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00383-6 · Cited by 122 · see citing works
RSV disease in infants and young children: Can we see a brighter future?
Baraldi, E., Lisi, G. C., Costantino, C., Heinrichs, J. H., Manzoni, P., Riccò, M., Roberts, M., & Vassilouthis, N. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2079322 · Cited by 99 · see citing works
The unfulfilled potential of mucosal immunization
Baker, J. R., Farazuddin, M., Wong, P. T., & O’Konek, J. J. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.05.002 · Cited by 72 · see citing works
Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines
Biagi, C., Dondi, A., Scarpini, S., Rocca, A., Vandini, S., Poletti, G., & Lanari, M. (2020) · Vaccines · doi:10.3390/vaccines8040672 · Cited by 61 · see citing works
Towards a unified classification for human respiratory syncytial virus genotypes
Ramaekers, K., Rector, A., Cuypers, L., Lemey, P., Keyaerts, E., & Ranst, M. A. V. (2020) · Virus Evolution · doi:10.1093/ve/veaa052 · Cited by 56 · see citing works
SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges
Cooper, D. M., Afghani, B., Byington, C. L., Cunningham, C. K., Golub, S., Lu, K. D., Radom-Aizik, S., Ross, L. F., Singh, J., Smoyer, W. E., et al. (2021) · Pediatric Research · doi:10.1038/s41390-021-01402-z · Cited by 55 · see citing works
Aging and Options to Halt Declining Immunity to Virus Infections
Palacios-Pedrero, M. Á., Osterhaus, A. D. M. E., Becker, T., Elbahesh, H., Rimmelzwaan, G. F., & Saletti, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.681449 · Cited by 55 · see citing works
Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults
Huang, F. S., Bernstein, D. I., Slobod, K. S., Portner, A., Takimoto, T., Russell, C. J., Meagher, M. M., Jones, B. G., Sealy, R. E., Coleclough, C., et al. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1779517 · Cited by 43 · see citing works
Overview of the respiratory syncytial virus vaccine candidate pipeline in Canada
Killikelly, A. M., Tunis, M. C., House, A., Quach, C., Vaudry, W., & MOORE, D. L. (2020) · Canada Communicable Disease Report · doi:10.14745/ccdr.v46i04a01 · Cited by 21 · see citing works
Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models
Saeland, E., van der Fits, L., Bolder, R., der Meer, M. H.-V., Drijver, J., van Polanen, Y., Vaneman, C., Tettero, L., Serroyen, J., Schuitemaker, H., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.12.043 · Cited by 18 · see citing works
Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein
Harshbarger, W. D., Abeyrathne, P. D., Tian, S., Huang, Y., Chandramouli, S., Bottomley, M. J., & Malito, E. (2021) · mAbs · doi:10.1080/19420862.2021.1955812 · Cited by 14 · see citing works
Serum Vitamin D Levels and Life-Threatening Respiratory Syncytial Virus Infection in Previously Healthy Infants
Ferolla, F. M., Yfran, E. W., Ballerini, M. G., Caratozzolo, A. M., Toledano, A., Giordano, A. C., Acosta, P. L., Cassinelli, H., Bergadá, I., Ropelato, M. G., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac033 · Cited by 14 · see citing works
Convergent structural features of respiratory syncytial virus neutralizing antibodies and plasticity of the site V epitope on prefusion F
Harshbarger, W. D., Tian, S., Wahome, N., Balsaraf, A., Bhattacharya, D. S., Jiang, D., Pandey, R., Tungare, K., Friedrich, K., Mehzabeen, N., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008943 · Cited by 14 · see citing works
The burden of respiratory syncytial virus in children under 5 years of age in Norway
Havdal, L. B., Bøås, H., Bekkevold, T., Kran, A. B., Rojahn, A. E., Størdal, K., Debes, S., Døllner, H., Nordbø, S. A., Barstad, B., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.12.008 · Cited by 14 · see citing works
T cells, more than antibodies, may prevent symptoms developing from respiratory syncytial virus infections in older adults
Salaun, B., Smedt, J. D., Vernhes, C., Moureau, A., Öner, D., Bastian, A. R., Janssens, M., Balla-Jhagjhoorsingh, S. S., Aerssens, J., Lambert, C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1260146 · Cited by 13 · see citing works
The COVID-19 Vaccine Landscape
Koch, T., Fathi, A., & Addo, M. M. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-63761-3_31 · Cited by 10 · see citing works
Association between early viral LRTI and subsequent wheezing development, a meta-analysis and sensitivity analyses for studies comparable for confounding factors
Kenmoe, S., Bowo‐Ngandji, A., Kengne-Ndé, C., Ebogo‐Belobo, J. T., Mbaga, D. S., Mahamat, G., Emoh, C. P. D., & Njouom, R. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249831 · Cited by 9 · see citing works
Effects of climatic factors on human parainfluenza 1, 2, and 3 infections in Cheonan, Republic of Korea
Oh, E. J., Kim, J. M., Joung, Y. H., & Kim, J. K. (2020) · Environmental Science and Pollution Research · doi:10.1007/s11356-020-11515-3 · Cited by 6 · see citing works
Retracted: Deceptology in cancer and vaccine sciences: Seeds of immune destruction‐mini electric shocks in mitochondria: Neuroplasticity‐electrobiology of response profiles and increased induced diseases in four generations – A hypothesis
Khatami, M. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.215 · Cited by 5 · see citing works
Retracted
Inhibition of AMP-activated protein kinase in respiratory syncytial virus infection activates lipid metabolism
González-García, L. D., Castillo, M. M., Vargas-Pavía, T. A., Ulloa-Aguilar, J. M., Arévalo-Romero, H., León‐Reyes, G., Helguera‐Repetto, A. C., García‐Cordero, J., & León‐Juárez, M. (2021) · Archives of Virology · doi:10.1007/s00705-021-04974-7 · Cited by 4 · see citing works
Development of a respiratory syncytial virus vaccine using human hepatitis B core-based virus-like particles to induce mucosal immunity
Huang, J.-M., Wang, S.-Y., Lai, M.-R., Tseng, Y., Chi, Y., & Huang, L. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.04.038 · Cited by 3 · see citing works
[Interpretation of "Expert recommendations for the prevention of common respiratory viral infections in neonates": problems faced by respiratory syncytial virus infection in neonates].
Chen, C., Wang, Y., & Shi, Y. (2025) · PubMed Central · doi:10.7499/j.issn.1008-8830.2409033 · Cited by 1 · see citing works
Virus-like particles containing the extracellular domain of G protein in combination with a CTL peptide of M2 elicit protection against respiratory syncytial virus infection without pulmonary disease
Qin, H., Luo, J., & Pan, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1625670 · Cited by 1 · see citing works
Advances in respiratory syncytial virus therapeutics: A comprehensive review of small-molecule inhibitors, monoclonal antibodies, and vaccines
Bai, G., Huang, X., & He, Y. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119092 · Cited by 1 · see citing works
Nirsevimab: An Extended Half-life Monoclonal Antibody for the Prevention of Infant Respiratory Syncytial Virus Infection
Domachowske, J. B. (2021) · touchREVIEWS in Respiratory & Pulmonary Diseases · doi:10.17925/usprd.2021.6.1.38 · Cited by 1 · see citing works
Surveillance of respiratory viruses at health facilities from across Kenya, 2014
Murunga, N., Nyawanda, B. O., Nyiro, J. U., Otieno, G. P., Kamau, E., Agoti, C. N., Lewa, C., Gichuki, A. M., Mutunga, M. N., Otieno, N. A., et al. (2022) · Wellcome Open Research · doi:10.12688/wellcomeopenres.17908.2 · Cited by 1 · see citing works
Surveillance of respiratory viruses at health facilities from across Kenya, 2014
Murunga, N., Nyawanda, B. O., Nyiro, J. U., Otieno, G. P., Kamau, E., Agoti, C. N., Lewa, C., Gichuki, A. M., Mutunga, M. N., Otieno, N. A., et al. (2023) · Wellcome Open Research · doi:10.12688/wellcomeopenres.17908.3 · Cited by 1 · see citing works
Aperçu de la filière de candidats vaccins contre le virus respiratoire syncytial au Canada
Killikelly, A. M., Tunis, M. C., House, A., Quach, C., Vaudry, W., & MOORE, D. L. (2020) · Relevé des maladies transmissibles au Canada · doi:10.14745/ccdr.v46i04a01f · Cited by 1 · see citing works
Surveillance of respiratory viruses at health facilities from across Kenya, 2014
Murunga, N., Nyawanda, B. O., Nyiro, J. U., Otieno, G. P., Kamau, E., Agoti, C. N., Lewa, C., Gichuki, A. M., Mutunga, M. N., Otieno, N. A., et al. (2022) · Wellcome Open Research · doi:10.12688/wellcomeopenres.17908.1 · Cited by 1 · see citing works
Current status of developments in the field of respiratory syncytial virus vaccines
Kotomina, T. S. (2025) · Journal of microbiology epidemiology immunobiology · doi:10.36233/0372-9311-675
Long-Term Trends in Human Parainfluenza Virus Types 1, 2, and 3 Infection in Korea (2007–2024)
Kim, K. G., Han, J.-B., Jeon, J., Jang, S. H., Wang, Q., & Kim, J. K. (2025) · Pathogens · doi:10.3390/pathogens14111159
Surveillance of respiratory viruses at health facilities from across Kenya, 2014
Murunga, N., Nyawanda, B. O., Nyiro, J. U., Otieno, G. P., Kamau, E., Agoti, C. N., Lewa, C., Gichuki, A. M., Mutunga, M. N., Otieno, N. A., et al. (2025) · Wellcome Open Research · doi:10.12688/wellcomeopenres.17908.4

Current progress on development of respiratory syncytial virus vaccine
Chang, J. (2011) · BMB Reports · doi:10.5483/bmbrep.2011.44.4.232 · Cited by 33 · see citing works
Respiratory syncytial virus vaccine development
Crowe, J. E. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00287-0 · Cited by 70 · see citing works
The journey to a respiratory syncytial virus vaccine
Mejías, A., Fernández, R. R., Oliva, S., Peeples, M. E., & Ramilo, O. (2020) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2020.03.017 · Cited by 140 · see citing works
Active prophylaxis for respiratory syncytial virus: current knowledge and future perspectives
Vittucci, A. C., Zangari, P., Ciarlitto, C., Camillo, C. D., Grandin, A., Cotugno, N., Marchili, M. R., & Villani, A. (2018) · Minerva Pediatrics · doi:10.23736/s0026-4946.18.05305-7 · Cited by 4 · see citing works
Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines
Biagi, C., Dondi, A., Scarpini, S., Rocca, A., Vandini, S., Poletti, G., & Lanari, M. (2020) · Vaccines · doi:10.3390/vaccines8040672 · Cited by 61 · see citing works

Authors: Rossey, I., & Saelens, X.
Affiliations: Ghent University (BE)
Corresponding author: Saelens, Xavier
ORCID: Rossey, Iebe
Saelens, Xavier
Venue: Expert Review of Vaccines
Publisher: Informa UK Limited
Published: 2019-10-03
Volume: 18
Issue: 10
Pages: 1053-1067
ISSN: 1476-0584 (ISSN-L)
1744-8395
DOI: 10.1080/14760584.2019.1675520
OpenAlex: W2979712475
Cited by: 32
References: 128
Citations by year: 2026: 1 · 2025: 5 · 2023: 2 · 2022: 5 · 2021: 11 · 2020: 8
FWCI: 0.88
Type: journal article
Language: en
Open access: closed
Locations: Expert Review of Vaccines (publishedVersion)
PubMed (publishedVersion)
Ghent University Academic Bibliography (Ghent University) (submittedVersion)
Funders: Fonds Wetenschappelijk Onderzoek
Vlaamse regering
Topics: Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
Keywords: respiratory syncytial virus, RSV vaccine development, live attenuated vaccine, subunit vaccine, vaccine clinical trials, correlates of protection, vaccine safety, vaccine immunogenicity
MeSH terms: Animals, Clinical Trials as Topic, Humans, Vaccination, Vaccines, Attenuated, Respiratory Syncytial Virus, Human, Respiratory Syncytial Virus Infections, Vaccines, Subunit, Respiratory Syncytial Virus Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Vaccines against human respiratory syncytial virus in clinical trials, where are we now?

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks